|
有投資者在投資者互動平台提問：董秘您好貴司有無涉及眼科創新藥的研究 光正眼科（002524.SZ）4月1日在投資者互動平台表示，公司學術相關研究主要集中在眼底視網膜疾病的診治及機製、（文章來源：每日經濟新聞）目 |
光算谷歌seo公司光算谷歌seo代运营光算谷歌外鏈光算谷歌seo光算蜘蛛池光算谷歌广告光算爬虫池光算谷歌推广光算蜘蛛池光算谷歌seo光算谷歌营销https://synapse.patsnap.com/drug/82ac8d77e262401fb9a592c181d05b9ehttps://synapse.patsnap.com/drug/48500d7cb3f14a2793e707afcc38ff52https://synapse.patsnap.com/article/seagen-acquisition-yields-positive-adcetris-phase-iii-results-for-pfizer-in-dlbclhttps://synapse.patsnap.com/drug/009172180b8e4d3286945301b095a7b8https://synapse.patsnap.com/article/what-are-dyrk-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/article/what-are-rh-factor-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/article/what-is-furazidin-used-forhttps://synapse.patsnap.com/article/ph-regulation-strategies-for-optimal-bioreactor-performancehttps://synapse.patsnap.com/article/what-is-the-mechanism-of-ropivacaine-mesylatehttps://synapse.patsnap.com/article/scinai-immunotherapeutics-reports-promising-in-vivo-results-for-psoriatic-skin-modelhttps://synapse.patsnap.com/drug/76bafeb91645471083d79cab60e759cbhttps://synapse.patsnap.com/drug/cc27aeca1ca44c5faf534d4e2041689ahttps://synapse.patsnap.com/drug/c8a6fc1a36cd4f51bcc79ce4292dd937https://synapse.patsnap.com/drug/dc26c2d8093d49028d1cc594c7b844d7https://synapse.patsnap.com/drug/f2ad5e0e42da41f3b1c8332857dd6752https://synapse.patsnap.com/article/neurocrine-biosciences-presented-cahtalyst%25E2%2584%25A2-phase-3-studies-and-cahtalog%25E2%2584%25A2-data-at-endo-2024https://synapse.patsnap.com/article/fda-approves-gomekli-as-first-adult-neurofibromatosis-drughttps://synapse.patsnap.com/drug/4fa220928ea44db9a339ed1814ca4e38https://synapse.patsnap.com/drug/94f64b786be4483783487c548962826fhttps://synapse.patsnap.com/drug/f705d5caa4144c5083d83a3d3efa35f8https://synapse.patsnap.com/article/what-is-mongersen-used-forhttps://synapse.patsnap.com/article/when-does-the-patent-for-baricitinib-expirehttps://synapse.patsnap.com/drug/9801286587594e8da8097e2a56f0eb0dhttps://synapse.patsnap.com/drug/cc629aa744a74a94b6a5467ed4afb620https://synapse.patsnap.com/drug/9e3107973549bb3dbc2641ff8a7712c4https://synapse.patsnap.com/article/enhanced-anti-myeloma-activity-of-gsk2857916-targeting-bcma-with-a-novel-fc-engineered-adchttps://synapse.patsnap.com/article/what-is-denosumab-bbdz-used-forhttps://synapse.patsnap.com/drug/ad88b5cabccb4919bfb1c5dd98e12bachttps://synapse.patsnap.com/drug/86fa82afce5844419c9107800e56b2ddhttps://synapse.patsnap.com/drug/0bc95918712547fb8c9dc6c06c132a02